Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

2016 • 29,943 citations

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

2017 • 14,809 citations

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

2010 • 14,016 citations

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

2015 • 7,407 citations

Pembrolizumab versus Ipilimumab in Advanced Melanoma

2015 • 5,239 citations

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

2011 • 4,304 citations

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

2013 • 3,290 citations

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

1995 • 2,842 citations

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

2014 • 2,071 citations

Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice

2001 • 1,761 citations

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

2014 • 1,704 citations

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma

2013 • 1,018 citations

Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice

2003 • 644 citations

Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody

2014 • 607 citations

Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy

2016 • 601 citations

Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy

2016 • 527 citations

Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study

2005 • 486 citations

CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma

2012 • 466 citations

The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network

2013 • 444 citations

Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma

2015 • 306 citations

PD-1 Protects against Inflammation and Myocyte Damage in T Cell-Mediated Myocarditis

2012 • 243 citations

PD-1 deficiency results in the development of fatal myocarditis in MRL mice

2010 • 233 citations

Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma

2015 • 223 citations

Clinical activity of ipilimumab for metastatic uveal melanoma

2013 • 184 citations

Programmed Death Ligand 1 Regulates a Critical Checkpoint for Autoimmune Myocarditis and Pneumonitis in MRL Mice

2008 • 177 citations

Anti-CTLA-4 antibody-induced Guillain–Barré syndrome in a melanoma patient

2011 • 171 citations

Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer

2011 • 148 citations

Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome

2015 • 139 citations

Late Onset Ipilimumab-Induced Pericarditis and Pericardial Effusion: A Rare but Life Threatening Complication

2015 • 124 citations

Ipilimumab-Induced Sarcoidosis in a Patient With Metastatic Melanoma Undergoing Complete Remission

2011 • 123 citations

Arthritis and Tenosynovitis Associated With the Anti-PD1 Antibody Pembrolizumab in Metastatic Melanoma

2014 • 119 citations

Autoimmune Inflammatory Myopathy after Treatment with Ipilimumab

2009 • 104 citations

Anti-PD1 Following Ipilimumab for Mucosal Melanoma: Durable Tumor Response Associated with Severe Hypothyroidism and Rhabdomyolysis

2013 • 100 citations

CTLA-4 Ablation and Interleukin-12–Driven Differentiation Synergistically Augment Cardiac Pathogenicity of Cytotoxic T Lymphocytes

2007 • 82 citations

Anti–Cytotoxic T-Cell Lymphocyte Antigen-4–Induced Regression of Spinal Cord Metastases in Association With Renal Failure, Atypical Pneumonia, Vision Loss, and Hearing Loss

2012 • 45 citations

Re-orienting the immune system

2013 • 29 citations